
What to know about RSV
Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and
Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and
The role of artificial intelligence (AI) in therapeutic research has become increasingly prominent in recent years, with the potential to revolutionize drug discovery, testing, and personalized medicine. This transformative technology
Poolbeg Pharma plc (LON:POLB), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has announced the appointment of Brendan Buckley as an Independent Non-Executive Director of
Artificial Intelligence (AI) and Machine Learning (ML) can be described as a branch of computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors
The pharmaceutical industry is continually seeking novel approaches to create and identify effective treatments that cater to medical requirements. The procedure of discovering drugs is a daunting process that demands
Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy,
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator. The US patent covers
The use of artificial intelligence (AI) in drug discovery is revolutionizing the pharmaceutical industry. AI-driven drug discovery has the potential to reduce the time and cost of drug development, while also improving
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the